Immediate Action: Simplify This Dangerous Polypharmacy Regimen
Your patient is on an unsafe, irrational polypharmacy regimen with two serotonergic antidepressants (vortioxetine + fluoxetine), three sedative-hypnotics (diazepam, temazepam, trazodone), and additional anxiolytics—this combination significantly increases risks of serotonin syndrome, cognitive impairment, falls, and benzodiazepine dependence while providing no additional therapeutic benefit. You must systematically deprescribe and optimize treatment.
Critical Safety Issues to Address First
Serotonin Syndrome Risk
The combination of vortioxetine 20 mg and fluoxetine 20 mg creates substantial risk for serotonin syndrome 1. These two serotonergic agents should never be combined without compelling justification. Fluoxetine's extremely long half-life (4-6 days for the parent compound, 4-16 days for active metabolite) means it persists for weeks after discontinuation 2.
Benzodiazepine Overuse
Your patient is on two benzodiazepines simultaneously (diazepam 5 mg BID scheduled + temazepam 15 mg PRN nightly). Guidelines explicitly warn that regular benzodiazepine use leads to tolerance, addiction, depression, cognitive impairment, and paradoxical agitation in ~10% of patients 2. Benzodiazepines should be time-limited and infrequent 3, 4.
Step-by-Step Deprescribing Strategy
Week 1-2: Eliminate Redundant Antidepressant
Discontinue fluoxetine immediately. There is zero evidence supporting dual SSRI/multimodal antidepressant therapy, and this combination violates basic pharmacologic principles 5.
- Vortioxetine 20 mg is already at maximum dose and has superior evidence for treatment-resistant depression with anxiety symptoms 6, 7, 8
- Fluoxetine adds only risk (serotonin syndrome, drug interactions via CYP2D6 inhibition) without benefit 5, 1
- Given fluoxetine's long half-life, no taper is needed—just stop it 2
Week 2-4: Consolidate Sedative-Hypnotics
Choose ONE agent for sleep, eliminate the others:
Option A (Preferred): Keep trazodone 25-50 mg at bedtime, discontinue both benzodiazepines
- Trazodone is guideline-recommended for insomnia in depression 3, 2
- Non-addictive, no cognitive impairment
- Can increase to 50-100 mg if needed for sleep
Option B: If severe insomnia persists, use temazepam 15 mg PRN (maximum 2-3 nights/week), discontinue diazepam and consider keeping trazodone
- Short-intermediate acting benzodiazepines like temazepam are least problematic when used infrequently 3, 2
Discontinue diazepam using slow taper (reduce by 1.25 mg every 5-7 days to avoid withdrawal) 2. Scheduled twice-daily benzodiazepines guarantee tolerance and dependence.
Week 4-6: Optimize Anxiolytic Strategy
Discontinue hydroxyzine. With vortioxetine optimized and benzodiazepines tapered, this adds minimal benefit and contributes to anticholinergic burden.
Keep melatonin 10 mg for sleep hygiene support (though evidence for chronic insomnia is limited 3).
What Should Be Happening Instead
Proper Antidepressant Optimization
Vortioxetine 20 mg monotherapy is your foundation 6, 7, 8:
- Demonstrated efficacy specifically in MDD with high anxiety (HAM-A ≥20) 7
- Superior to agomelatine in treatment-resistant depression 7, 8
- Dose-response relationship shows 20 mg provides greatest benefit 7
- Well-tolerated even with rapid titration to 20 mg 6
- Remission rates of 32-55% after SSRI/SNRI failure 6
Give vortioxetine an adequate trial: 8-12 weeks at 20 mg before declaring treatment failure 9, 6.
If Still Inadequate Response After 8-12 Weeks
Second-line augmentation options (choose ONE) 10, 11:
- Add aripiprazole 2-5 mg daily (best evidence for augmentation in treatment-resistant depression with anxiety 12)
- Add lithium 300-600 mg daily (target level 0.4-0.8 mEq/L) 2
- Switch to different antidepressant (e.g., duloxetine, mirtazapine) rather than combining 10
Do NOT combine multiple antidepressants 9, 10. No evidence supports this approach.
Non-Pharmacologic Interventions (Essential)
Cognitive Behavioral Therapy for Insomnia (CBT-I) is STANDARD treatment 3:
- More effective long-term than medications
- Addresses perpetuating factors
- Facilitates medication tapering
- Should be implemented NOW while deprescribing
CBT for depression and anxiety 5:
- Combination CBT + antidepressant superior to either alone in anxiety disorders 5
- Prevents relapse better than medication alone 9
Monitoring During Transition
Weeks 1-4 (Critical Period)
- Weekly contact to assess withdrawal symptoms, mood stability, sleep quality 9
- Monitor for serotonin syndrome signs (agitation, tremor, diaphoresis, confusion) 1
- Assess benzodiazepine withdrawal (anxiety, insomnia, tremor, seizures in severe cases) 2
Weeks 4-12
- Every 2-3 weeks to assess antidepressant response 9
- Use standardized scales (PHQ-9 for depression, GAD-7 for anxiety)
- Functional assessment (work, relationships, activities)
Common Pitfalls to Avoid
Don't add more medications when polypharmacy is the problem. Simplify first.
Don't continue benzodiazepines "because the patient has been on them for years." This guarantees continued dependence and cognitive decline 3, 2, 4.
Don't combine antidepressants without clear evidence. This is not supported by guidelines and increases adverse effects without improving outcomes 9, 10.
Don't declare treatment failure before adequate trial. Vortioxetine needs 8-12 weeks at maximum dose 6.
Don't ignore psychotherapy. Medication alone has 50% response rate; combination therapy is superior 9, 5.
Expected Timeline
- Weeks 1-4: Deprescribing phase, symptoms may temporarily worsen
- Weeks 4-8: Stabilization on simplified regimen
- Weeks 8-12: Full assessment of vortioxetine efficacy
- Week 12+: Consider augmentation only if inadequate response persists
The goal is ONE antidepressant, ONE sleep aid (preferably non-benzodiazepine), and evidence-based psychotherapy—not seven psychotropic agents that create more problems than they solve.